Dear All: Below my signature, find details of 4 new meetings and (collectively) 4 active or upcoming grant opportunities. One of the grants has a 6 Sep deadline, so look quickly! At the very bottom of the email you will find an integrated summary of all upcoming meetings … there is a lot going on!
Dear All: Two updates today. First, our colleagues at London School of Economics have just published a review of antibiotic innovation incentives that includes a detailed review of some of the currently available sources of funding (Simpkin VL et al., Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot, 1 Nov 2017). As
Dear All: For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).
Dear All: We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this! Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to
Dear All: It is great to see that the UK Department of Health (DH) and the Chinese Ministry of Science and Technology (MoST) have today announced the size, scope and eligibility for the UK-China AMR Collaboration that was initially announced in 2016. DH will to invest up to £10 million in UK businesses and MoSt will provide to 60 million
Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France,
Dear All: Three important documents were released at / during / around the World Economic Forum meeting that occurred this week in Davos. First and foremost, we have the final report from DRIVE-AB. It’s a substantial document and you’ll need to set aside an afternoon to read it. As a way to get started, my 11 Sep 2017
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given
Dear All, This email was just today received from the team leading the NHS England antibiotic procurement project (go here for a prior newsletter describing the project): Dear Stakeholders, In November 2019, we held a stakeholder webinar to share our response to the comments raised in targeted engagement and to outline proposals for the procurement process.
Dear All, We learned today during the BEAM AMR conference (link) that EMA released a call on 7 June 202 for comments on their draft Network Strategy to 2025 that considers how “the European medicines agencies’ network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges